Alkermes plc
ALKS
株式のランク
#2633
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
株価
$43.05
最終同期: 2026-10-19
時価総額
$7.22B
変化（1日）
4.43%
変化（1年）
38.95%
国
IE
取引 Alkermes plc (ALKS)
カテゴリー
Healthcare
Alkermes plc（ALKS）の株式分割履歴
Alkermes plc株（シンボル：ALKS）は合計で1回の株式分割を実施しました。
最新の株式分割はMay 15, 2000に行われました。
May 15, 2000より前に購入されたALKS株は、現在2ALKS株に相当します。
最新の株式分割はMay 15, 2000に行われました。
May 15, 2000より前に購入されたALKS株は、現在2ALKS株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2000-05-15 | 2:1 | x2 | x2 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
